Technical considerations for circulating tumor DNA detection in oncology

References

• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–548.
   PubMed Web of Science ®Google Scholar
• Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35(3):347–376.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–435.
   PubMed Web of Science ®Google Scholar
• Peng M, Chen C, Hulbert A, et al. Non-blood circulating tumor DNA detection in cancer. Oncotarget. 2017;8(40):69162–69173.
   PubMedGoogle Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–990.
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–586.
   PubMed Web of Science ®Google Scholar
• Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392(10149):777-786.
   PubMed Web of Science ®Google Scholar
• Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27:858–863.
   PubMed Web of Science ®Google Scholar
• Su SF, de Castro Abreu AL, Chihara Y, et al. A panel of three markers hyper-and hypomethylated in urine sediments accurately predictsbladder cancer recurrence. Clin Cancer Res. 2014 Apr 1;20(7):1978–1989.
   PubMed Web of Science ®Google Scholar
• Shlien A, Malkin D. Copy number variations and cancer. Genome Med. 2009;1(6):62.
   PubMedGoogle Scholar
• Merker JD, Oxnard GR, Compton C. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018 Jun 1;36(16):1631–1641.
   PubMed Web of Science ®Google Scholar
• El Messaoudi S, Rolet F, Mouliere F, et al. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222–230.
   PubMed Web of Science ®Google Scholar
• Lee TH, Montalvo L, Chrebtow V, et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion. 2001;41:276–282.
   PubMed Web of Science ®Google Scholar
• Medina Diaz I, Nocon A, Mehnert DH, et al. Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One. 2016 Nov 10;11(11):e0166354.
   PubMed Web of Science ®Google Scholar
• Norton SE, Luna KK, Lechner JM, et al. A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device. J Clin Lab Anal. 2013;27:305–311.
   PubMed Web of Science ®Google Scholar
• Wong D, Moturi S, Angkachatchai V, et al. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem. 2013;46:1099–1104.
   PubMed Web of Science ®Google Scholar
• Henao Diaz E, Yachnin J, Grönberg H, et al. The in vitro stability of circulating tumour DNA. PLoS One. 2016;11(12):e0168153.
   PubMed Web of Science ®Google Scholar
• Parpart-Li S, Bartlett B, Popoli M, et al. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res. 2017;23(10):2471–2477.
   PubMed Web of Science ®Google Scholar
• Toro PV, Erlanger B, Beaver JA, et al. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem. 2015;48(15):993–998.
   PubMed Web of Science ®Google Scholar
• Chan KC, Yeung SW, Lui WB, et al. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem. 2005;51:781–784.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;371(2):187–188.
   PubMedGoogle Scholar
• Ponti G, Maccaferri M, Micali S, et al. Seminal cell free DNA concentration levels discriminate between prostate cancer and benignprostatic hyperplasia. Anticancer Res. 2018;38(9):5121–5125.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Melnikova VO, Karlovich C, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016;11(10):1690–1700.
   PubMed Web of Science ®Google Scholar
• Su YH, Wang M, Brenner DE, et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn. 2004;6(2):101–107.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu Y, Zhong W, et al. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutationdetection using droplet digital PCR. Oncotarget. 2017;8(4):5861–5873.
   PubMed Web of Science ®Google Scholar
• Haselmann V, Ahmad-Nejad P, Geilenkeuser WJ, et al. Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). Clin Chem Lab Med. 2018;56(2):220-228.
   PubMed Web of Science ®Google Scholar
• Lu JL, Liang ZY. Circulating free DNA in the era of precision oncology: pre- and post-analytical concerns. Chronic Dis Transl Med. 2016 Dec 22;2(4):223–230.
   PubMedGoogle Scholar
• Malentacchi F, Pizzamiglio S, Verderio P, et al. Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIADNAplas external quality assessment experience. Clin Chem Lab Med. 2015;53:1935–1942.
   PubMed Web of Science ®Google Scholar
• Yuan H, Zhu ZZ, Lu Y, et al. A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis. Yonsei Med J. 2012;53:132–137.
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Schmidt B, Weickmann S, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011;412:2085–2088.
   PubMed Web of Science ®Google Scholar
• Kloten V, Rüchel N, Brüchle NO, et al. Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR. Oncotarget. 2017;8(49):86253–86263.
   PubMedGoogle Scholar
• Garcia J, Dusserre E, Cheynet V, et al. Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study. Oncotarget. 2017;8(50):87980–87996.
   PubMedGoogle Scholar
• Keppens C, Palma JF, Das PM. Detection of EGFR variants in plasma: a multilaboratory comparison of a real-time PCR EGFR Mutation test in Europe. J Mol Diagn. 2018;20(4):483–494.
   PubMed Web of Science ®Google Scholar
• Arriola E, Paredes-Lario A, García-Gomez R, et al. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFRmutation status in advanced NSCLC: spanish data subset from ASSESS. Clin Transl Oncol. 2018. DOI:10.1007/s12094-018-1855-y.
   PubMed Web of Science ®Google Scholar
• Cui S, Ye L, Wang H, et al. Use of SuperARMS®EGFR mutation detection kit to detect EGFR in plasma cell-free DNA of patients with lung adenocarcinoma. Clin Lung Cancer. 2018;19(3):e313-e322.
   PubMed Web of Science ®Google Scholar
• Feng WN, Gu WQ, Zhao N, et al. Comparison of the SuperARMS and droplet digital PCR for detecting EGFR mutation in ctDNAFrom NSCLC patients. Transl Oncol. 2018;11(2):542–545.
   PubMed Web of Science ®Google Scholar
• Liu X, Lu Y, Zhu G, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013;66(12):1065–1069.
   PubMed Web of Science ®Google Scholar
• Liu HE, Vuppalapaty M, Lemaire C. Epidermal Growth Factor Receptor (EGFR) mutational detection in VTX-1 isolated CTCs, ctDNA from the same tube of blood, and comparison to tumor tissue in Non-Small-Cell-Lung-Cancer (NSCLC) patients. J Clin Oncol. 2017;35, no. 15_suppl.
   Google Scholar
• Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med. 2017;5(3):46.
   PubMed Web of Science ®Google Scholar
• Biocartis. Liquid biopsy assays. ctKRAS. [cited 2017 Dec 21]. Available from: https://biocartis.com/idylla-ctkras-mutation-test
   Google Scholar
• Biocartis. Liquid biopsy assays. ctNRAS-BRAF. [cited 2017 Dec 21]. Available from: https://biocartis.com/idylla-ctnras-braf-mutation-test
   Google Scholar
• Janku F, Huang HJ, Claes B, et al. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Mol Cancer Ther. 2016;15(6):1397–1404.
   PubMed Web of Science ®Google Scholar
• Schreuer M, Meersseman G, Van Den Herrewegen S, et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. J Transl Med. 2016;14:95.
   PubMed Web of Science ®Google Scholar
• Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a crossplatform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90:509–515.
   PubMed Web of Science ®Google Scholar
• Milbury CA, Li J, Liu P, et al. COLD PCR: improving the sensitivity of molecular diagnostics assays. Expert Rev Mol Diagn. 2011;11(2):159–169.
   PubMed Web of Science ®Google Scholar
• Mauger F, How-Kit A, Tost J. COLD-PCR technologies in the area of personalized medicine: methodology and applications. Mol Diagn Ther. 2017;21(3):269–283.
   PubMed Web of Science ®Google Scholar
• Milbury CA, Li J, Mike Makrigiorgos GM. Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res. 2011;39(1):e2.
   PubMed Web of Science ®Google Scholar
• Castellanos-Rizaldos E, Liu P, Milbury CA, et al. Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment. Clin Chem. 2012;58(7):1130–1138.
   PubMed Web of Science ®Google Scholar
• How-Kit A, Tost J. Pyrosequencing®-based identification of low-frequency mutations enriched through enhanced-ice-COLD-PCR. Methods Mol Biol. 2015;1315:83–101.
   PubMedGoogle Scholar
• Tost J. The clinical potential of enhanced-ice-COLD-PCR. Expert Rev Mol Diagn. 2016;16(3):265–268.
   PubMed Web of Science ®Google Scholar
• How Kit A, Mazaleyrat N, Daunay A, et al. Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification. Hum Mutat. 2013;34:1568–1580.
   PubMed Web of Science ®Google Scholar
• Sefrioui D, Mauger F, Leclere L, et al. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients. Clin Chim Acta. 2017;465:1–4.
   PubMed Web of Science ®Google Scholar
• How Kit A, Lebbe C, Bousard A, et al. Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR. Anal Bioanal Chem. 2014;406:5513–5520.
   PubMed Web of Science ®Google Scholar
• Song N, Zhong X, Li Q. Real-time bidirectional pyrophosphorolysis-activated polymerization for quantitative detection of somatic mutations. PLoS One. 2014;9(4):e96420.
   PubMed Web of Science ®Google Scholar
• Madic J, Piperno-Neumann S, Servois V, et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res. 2012;18(14):3934–3941.
   PubMed Web of Science ®Google Scholar
• Cabel L, Riva F, Servois V, et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 2017;28(8):1996–2001.
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–9826.
   PubMed Web of Science ®Google Scholar
• Cottrell SE, Laird PW. Sensitive detection of DNA methylation. Ann N Y Acad Sci. 2003;983:120–130.
   PubMed Web of Science ®Google Scholar
• Scher MB, Elbaum MB, Mogilevkin Y, et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol. 2012;188:2101–2107.
   PubMed Web of Science ®Google Scholar
• Costa VL, Henrique R, Danielsen SA, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010;16:5842–5851.
   PubMed Web of Science ®Google Scholar
• Karnes RJ, Fernandez CA, Shuber AP. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc. 2012;87:835–842.
   PubMed Web of Science ®Google Scholar
• Dahmcke CM, Steven KE, Larsen LK, et al. A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria. Eur Urol. 2016;70(6):916-919.
   PubMed Web of Science ®Google Scholar
• Song BP, Jain S, Lin SY, et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn. 2012;14:112–119.
   PubMed Web of Science ®Google Scholar
• Brikun I, Nusskern D, Decatus A, et al. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urineDNA. Clin Epigenetics. 2018;10:91.
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Mengual L, Ingelmo-Torres M, et al. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics. 2018;10:71.
   PubMed Web of Science ®Google Scholar
• Righini CA, de Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res. 2007;13:1179–1185.
   PubMed Web of Science ®Google Scholar
• Sun W, Zaboli D, Wang H, et al. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res. 2012;18:1082–1091.
   PubMed Web of Science ®Google Scholar
• Demokan S, Chang X, Chuang A, et al. KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer. 2010;127:2351–2359.
   PubMed Web of Science ®Google Scholar
• Schussel J, Zhou XC, Zhang Z, et al. EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res. 2013;19:3268–3275.
   PubMed Web of Science ®Google Scholar
• Konno S, Morishita Y, Fukasawa M, et al. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma. Cancer. 2004;102:348–354.
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 2005;11:6505–6511.
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Stastny V, Suzuki M, et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett. 2007;247:56–71.
   PubMed Web of Science ®Google Scholar
• Destro A, Bianchi P, Alloisio M, et al. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer. 2004;44:23–32.
   PubMed Web of Science ®Google Scholar
• Wang YC, Hsu HS, Chen TP, et al. Molecular diagnostic markers for lung cancer in sputum and plasma. Ann N Y Acad Sci. 2006;1075:179–184.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999;96:9236–9241.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Rosenfeld N, Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;369:93–94.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra224.
   Web of Science ®Google Scholar
• Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83:8604–8610.
   PubMed Web of Science ®Google Scholar
• Yu Q, Huang F, Zhang M, et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients. Mol Med Rep. 2017;16(2):1157–1166.
   PubMed Web of Science ®Google Scholar
• Whale AS, Huggett JF, Tzonev S. Fundamentals of multiplexing with digital PCR. Biomol Detect Quantif. 2016;10:15–23.
   PubMedGoogle Scholar
• Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59:1722–1731.
   PubMed Web of Science ®Google Scholar
• Hrebien S, O’Leary B, Beaney M, et al. Reproducibility of digital PCR assays for circulating tumor DNA analysis in advanced breastcancer. PLoS One. 2016;11(10):e0165023.
   PubMed Web of Science ®Google Scholar
• Jones GM, Busby E, Garson JA, et al. Digital PCR dynamic range is approaching that of real-time quantitative PCR. Biomol Detect Quantif. 2016;10:31–33.
   PubMedGoogle Scholar
• Zhong Q, Bhattacharya S, Kotsopoulos S, et al. Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab Chip. 2011;11:2167–2174.
   Web of Science ®Google Scholar
• Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20(10):2643–2650.
   PubMed Web of Science ®Google Scholar
• Madic J, Zocevic A, Senlis V, et al. Three-color crystal digital PCR. Biomol Detect Quantif. 2016;10:34–46.
   PubMedGoogle Scholar
• Jovelet C, Madic J, Remon J, et al. Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer. PLoS One. 2017;12(8):e0183319.
   PubMed Web of Science ®Google Scholar
• Dong L, Meng Y, Sui Z, et al. Comparison of four digital PCR platforms for accurate quantification of DNA copy number of a certified plasmid DNA reference material. Sci Rep. 2015;5:13174.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhao J, Cui L, et al. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clin Transl Oncol. 2016;19:332–340.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102:16368–16373.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, He Y, et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3:551–559.
   PubMed Web of Science ®Google Scholar
• Li M, Diehl F, Dressman D, et al. BEAMing up for detection and quantification of rare sequence variants. Nat Methods. 2006;3:95–97.
   PubMed Web of Science ®Google Scholar
• García-Foncillas J, Alba E, Aranda E, et al. Incorporating beaming technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol. 2017;28(12):2943–2949.
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012;18:3462–3469.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res. 2011;17:7808–7815.
   PubMed Web of Science ®Google Scholar
• Morelli MP, Overman MJ, Dasari A, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26:731–736.
   PubMed Web of Science ®Google Scholar
• Vidal J, Muinelo L, Dalmases A, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28:1325–1332.
   PubMed Web of Science ®Google Scholar
• Toledo RA, Cubillo A, Vega E, et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget. 2017;8:35289–35300.
   PubMedGoogle Scholar
• Mouliere F, El Messaoudi S, Gongora C, et al. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol. 2013;6:319–328.
   PubMed Web of Science ®Google Scholar
• Shin SJ, Chun SM, Kim TI, et al. Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PLoS One. 2017;12(5):e0176340.
   PubMed Web of Science ®Google Scholar
• Wee EJ, Wang Y, Tsao SC, et al. Simple, sensitive and accurate multiplexdetection of clinically important melanoma DNA mutations in circulating tumour DNA with SERS nanotags. Theranostics. 2016;6:1506–1513.
   PubMed Web of Science ®Google Scholar
• Mosko MJ, Nakorchevsky AA, Flores E, et al. Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry. J Mol Diagn. 2016;18(1):23–31.
   PubMed Web of Science ®Google Scholar
• Cai C, Guo Z, Cao Y, et al. A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA). Nanotheranostics. 2018;2(1):12–20.
   PubMedGoogle Scholar
• Nguyen AH, Sim SJ. Nanoplasmonic biosensor: detection and amplification of dual bio-signatures of circulating tumor DNA. Biosens Bioelectron. 2015;67:443–449.
   PubMed Web of Science ®Google Scholar
• Harlé A, Filhine-Tresarrieu P, Husson M, et al. Rare RAS mutations in metastatic colorectal cancer detected during routine RAS genotyping using next generation sequencing. Target Oncol. 2016;11(3):363–370.
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra168.
   Web of Science ®Google Scholar
• Gale D, Lawson ARJ, Howarth K, et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS One. 2018;13(3):e0194630.
   PubMed Web of Science ®Google Scholar
• Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(23):9530–9535.
   PubMed Web of Science ®Google Scholar
• Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26:1715–1722.
   PubMed Web of Science ®Google Scholar
• Fredebohm J, Mehnert DH, Lober AK, et al. Detection and quantification of KIT mutations in ctDNA by plasma safe-SeqS. Adv Exp Med Biol. 2016;924:187–189.
   PubMed Web of Science ®Google Scholar
• Lanman RB, Mortimer SA, Zill OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurateevaluation of cell-free circulating tumor DNA. PLoS One. 2015;10(10):e0140712.
   PubMed Web of Science ®Google Scholar
• Patel KM, van der Vos KE, Smith CG, et al. Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer. Sci Rep. 2017;7(1):5554.
   PubMedGoogle Scholar
• Clark TA, Chung JH, Kennedy M, et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J Mol Diagn. 2018;20(5):686–702.
   PubMed Web of Science ®Google Scholar
• Janku F, Zhang S, Waters J, et al. Development and validation of an ultradeep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res. 2017 Sep 15;23(18):5648–5656.
   PubMed Web of Science ®Google Scholar
• Namløs HM, Boye K, Mishkin SJ, et al. Non-invasive detection of ctDNA reveals intratumour heterogeneity and is associated with tumour burden in gastrointestinal stromal tumour. Mol Cancer Ther. 2018;pii:molcanther.0174.2018.
   Google Scholar
• Ion torrent. Detecting primary tumor drivers and resistance mutations using cell-free total nucleic acid. [cited 2018 sep 12]. Available from: http://assets.thermofisher.com/TFS-Assets/CSD/Application-Notes/liquid-biopsy-white-paper-cnv-fusion.pdf
   Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548–554.
   PubMed Web of Science ®Google Scholar
• Bratman SV, Newman AM, Alizadeh AA, et al. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn. 2015;15:715–719.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM, Newman AM, et al. Noninvasive genotyping and assessment of treatment response in diffuse large B cell lymphoma. Blood. 2015;126:114.
   Web of Science ®Google Scholar
• Khan KH, Cunningham D, Werner B, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 2018.
   Web of Science ®Google Scholar
• Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016;34:2404–2415.
   PubMedGoogle Scholar
• Mansukhani S, Barber LJ, Kleftogiannis D, et al. Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error-corrected circulating tumor DNA sequencing. Clin Chem. 2018;pii:289629.
   Google Scholar
• Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–555.
   PubMed Web of Science ®Google Scholar
• Pécuchet N, Rozenholc Y, Zonta E, et al. Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA. Clin Chem. 2016;62(11):1492–1503.
   PubMed Web of Science ®Google Scholar
• Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9:403.
   Web of Science ®Google Scholar
• Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324.
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497:108–112.
   PubMed Web of Science ®Google Scholar
• Koeppel F, Blanchard S, Jovelet C, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017 Nov 21;12(11):e0188174.
   PubMed Web of Science ®Google Scholar
• Chen S, Liu M, Zhou Y. Bioinformatics analysis for cell-free tumor DNA sequencing data. Methods Mol Biol. 2018;1754:67–95.
   PubMedGoogle Scholar
• Kirkizlar E, Zimmermann B, Constantin T, et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol. 2015;8(5):407–416.
   PubMed Web of Science ®Google Scholar
• Stover DG, Parsons HA, Ha G, et al. Association of cell free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018 Feb 20;36(6):543–553. Epub 2018 Jan 3. .
   PubMed Web of Science ®Google Scholar
• Østrup O, Ahlborn LB, Lassen U, et al. Detection of copy number alterations in cell-free tumor DNA from plasma. BBA Clin. 2017;7:120–126.
   PubMed Web of Science ®Google Scholar
• Chicard M, Boyault S, Colmet Daage L, et al. Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. Clin Cancer Res. 2016;22(22):5564–5573.
   PubMed Web of Science ®Google Scholar